Inactive Instrument

PDI, Inc. Stock Nasdaq

US69329V1008

Healthcare Facilities & Services

End-of-day quote Nasdaq
- ^USD	-

11/08	Interpace Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
13/05	Interpace Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Analysts' recommendations : PDI, Inc.

26/01/21

Interpace Biosciences : HC Wainwright Adjusts Interpace Biosciences' Price Target to $6 From $10, Keeps Buy Rating

More recommendations

Managers and Directors : PDI, Inc.

Manager	Title	Age	Since
Thomas Burnell CEO	Chief Executive Officer	64	01/12/2020
Christopher McCarthy DFI	Director of Finance/CFO	34	21/04/2023
Nicole Massoll CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Stephen Sullivan CHM	Chairman	79	21/06/2016
Joseph Keegan BRD	Director/Board Member	73	01/01/2016
Fortunato Rocca BRD	Director/Board Member	64	22/01/2020

More insiders

Medical & Diagnostic Laboratories

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NATERA, INC.	+0.07%	+4.19%	+104.39%	+490.28%	48.79B
LABCORP HOLDINGS INC.	+0.24%	+1.85%	+20.86%	+58.60%	27.23B
SONIC HEALTHCARE LIMITED	+0.20%	-14.69%	-15.69%	-37.60%	7.1B
RADNET, INC.	-1.45%	-0.24%	+6.79%	+134.77%	6.02B
DR. LAL PATHLABS LIMITED	-0.05%	+2.61%	+17.06%	+77.10%	3.39B
GENEDX HOLDINGS CORP.	-1.16%	+12.04%	-29.31%	+1,999.76%	2.69B
NEOGENOMICS, INC.	+7.31%	+11.92%	+178.21%	+33.91%	2.23B
FLEURY S.A.	+0.32%	+2.52%	+32.44%	+24.93%	1.97B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-1.45%	+1.24%	-7.80%	-51.91%	1.94B
Average	+0.42%	+2.14%	+34.10%	+303.32%	11.26B
Weighted average by Cap.	+0.03%	+2.11%	+59.35%	+313.02%

See all sector performances

Interpace Biosciences, Inc. provides esoteric molecular diagnostic testing and pathology services to aid physicians in the evaluation of cancer risk. The Companyâ€™s clinical services business commercializes clinically useful molecular diagnostic tests and molecular pathology services. The Company develops and commercializes genomic tests and related first-line assays that can personalize medicine to help improve patient diagnosis and management. It has five commercialized molecular diagnostic tests: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, and RespriDX. PancraGEN is a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physiciansâ€™ better risk-stratify pancreaticobiliary cancers using the Companyâ€™s proprietary PathFinderTG platform. PanDNA is an alternate reporting option of the PathFinderTG platform, which provides physicians the molecular only information. ThyGeNEXT is an oncogenic mutation panel that helps rule-in and rule-out malignancy in thyroid nodules.

Employees

Sector

Healthcare Facilities & Services

Calendar

27/08 Significant Split/Dividend

More about the company

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

Market Cap	40.17M 34.47M 32.29M 29.54M 55.63M 3.84B 55.84M 382M 149M 1.93B 151M 148M 6.4B	P/E 2024	34.2x	P/E 2025	6.95x
Enterprise Value	38.84M 33.34M 31.23M 28.57M 53.8M 3.71B 54M 370M 144M 1.87B 146M 143M 6.19B	EV / Sales 2024	0.35x	EV / Sales 2025	0.11x
Free-Float	8.77%	Yield 2024 *	-	Yield 2025	-

11/08	Interpace Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
13/05	Interpace Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
31/03	Interpace Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
21/01	Interpace Biosciences Announces Preliminary and Unaudited Revenue Results for the Year 2025	CI
21/01	Interpace Biosciences, Inc. Provides Preliminary Unaudited Revenue Guidance for the Full Year of 2025 and Initiates Revenue Guidance for the Full Year of 2026	CI
04/12	Interpace Biosciences Announces Early Repayment of Debt to BroadOak Capital Partners	CI
13/11	Interpace Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
13/11	Interpace Biosciences Q3 revenue down	RE
08/08/25	Interpace Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
09/05/25	Interpace Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
09/05/25	Interpace Biosciences, Inc. Provides Revenue Guidance for the Full-Year 2025	CI
01/04/25	Interpace Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
10/01/25	Interpace Diagnostics® to No Longer Offer PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk	CI

27/08	Interpace Biosciences Announces Reverse Stock Split to Support Proposed Nasdaq Uplisting	AQ
11/08	Interpace Biosciences Announces Second Quarter 2026 Financial and Business Results	AQ
13/05	Interpace Biosciences Announces First Quarter 2026 Financial and Business Results	AQ
31/03	Interpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results	AQ
21/01	Interpace Biosciences Announces Preliminary 2025 Revenue, 2026 Revenue Guidance and Simplification of Capital Structure	AQ

	2024	2025
Net sales	46.93M 40.27M 37.73M 34.51M 65M 4.48B 65.23M 446M 175M 2.26B 176M 172M 7.48B	38.73M 33.24M 31.14M 28.48M 53.64M 3.7B 53.84M 368M 144M 1.86B 145M 142M 6.17B
Net income	6.7M 5.75M 5.39M 4.93M 9.28M 640M 9.32M 63.76M 24.93M 323M 25.16M 24.61M 1.07B	24.58M 21.09M 19.76M 18.08M 34.04M 2.35B 34.16M 234M 91.4M 1.18B 92.27M 90.25M 3.92B
Net Debt	4.4M 3.77M 3.53M 3.23M 6.09M 420M 6.11M 41.81M 16.35M 212M 16.5M 16.14M 700M	-1.32M -1.13M -1.06M -972K -1.83M -126M -1.84M -12.58M -4.92M -63.66M -4.96M -4.86M -211M

PDI, Inc. Stock Nasdaq

Stocks

US69329V1008

Healthcare Facilities & Services

Valuation : PDI, Inc.

Latest news : PDI, Inc.

Analysts' recommendations : PDI, Inc.

Press Releases : PDI, Inc.

Managers and Directors : PDI, Inc.

Medical & Diagnostic Laboratories

Financials

Company Profile